Paclitaxel pharmacokinetics and pharmacodynamics

C. M. Kearns, L. Gianni, M. J. Egorin

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-E(max) (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalSeminars in Oncology
Volume22
Issue number3 SUPPL. 6
Publication statusPublished - 1995

Fingerprint

Paclitaxel
Pharmacokinetics
Neutropenia
Area Under Curve
Sigmoid Colon

ASJC Scopus subject areas

  • Oncology

Cite this

Kearns, C. M., Gianni, L., & Egorin, M. J. (1995). Paclitaxel pharmacokinetics and pharmacodynamics. Seminars in Oncology, 22(3 SUPPL. 6), 16-23.

Paclitaxel pharmacokinetics and pharmacodynamics. / Kearns, C. M.; Gianni, L.; Egorin, M. J.

In: Seminars in Oncology, Vol. 22, No. 3 SUPPL. 6, 1995, p. 16-23.

Research output: Contribution to journalArticle

Kearns, CM, Gianni, L & Egorin, MJ 1995, 'Paclitaxel pharmacokinetics and pharmacodynamics', Seminars in Oncology, vol. 22, no. 3 SUPPL. 6, pp. 16-23.
Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Seminars in Oncology. 1995;22(3 SUPPL. 6):16-23.
Kearns, C. M. ; Gianni, L. ; Egorin, M. J. / Paclitaxel pharmacokinetics and pharmacodynamics. In: Seminars in Oncology. 1995 ; Vol. 22, No. 3 SUPPL. 6. pp. 16-23.
@article{93f452bb18ab4ed8a1e73c9ddfacbbdb,
title = "Paclitaxel pharmacokinetics and pharmacodynamics",
abstract = "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-E(max) (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.",
author = "Kearns, {C. M.} and L. Gianni and Egorin, {M. J.}",
year = "1995",
language = "English",
volume = "22",
pages = "16--23",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 6",

}

TY - JOUR

T1 - Paclitaxel pharmacokinetics and pharmacodynamics

AU - Kearns, C. M.

AU - Gianni, L.

AU - Egorin, M. J.

PY - 1995

Y1 - 1995

N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-E(max) (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.

AB - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-E(max) (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.

UR - http://www.scopus.com/inward/record.url?scp=0029044165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029044165&partnerID=8YFLogxK

M3 - Article

C2 - 7597430

AN - SCOPUS:0029044165

VL - 22

SP - 16

EP - 23

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 6

ER -